Pharmaceutical titan Eli Lilly has delivered a quarterly report that dramatically surpassed market forecasts, sending waves ...

Eli Lilly (LLY) stock rises after reporting that sales of its weight-loss drugs more than doubled in the third quarter. The ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

Eli Lilly has reported that its interleukin-13 (IL-13) inhibitor Ebglyss (lebrikizumab-lbkz) showed sustained skin clearance ...

Two Texas compounding pharmacies are the latest to get sued in Eli Lilly’s multistate battle to stop sales of replica ...

Eli Lilly beats Q3 2025 estimates and raises guidance as strong GLP-1 drug sales from Mounjaro and Zepbound lift profit and ...

LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and ...

A particularly noteworthy achievement emerged this quarter: Eli Lilly's tirzepatide franchise overtook Merck's cancer immunotherapy Keytruda to become the world's highest-grossing medication. This ...

A year after earning FDA approval for Kisunla, Eli Lilly is shining a light on the anti-amyloid Alzheimer’s disease therapy in its first branded campaign. The “Light Up Tomorrow” direct-to-consumer ...

The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company ...

Eli Lilly & Co. has joined forces with artificial intelligence chipmaker Nvidia Corp. to develop what the companies describe as the most powerful supercomputer operated by a pharmaceutical firm. The ...